# Plain Language Patient Summary How might diabetes medicines help the heart in people living with type 2 diabetes?

Date of Summary: December 2020

- This plain language patient summary is intended for a non-clinician audience. It summarizes content from one chapter in the supplement **Type 2 Diabetes 2021**, a collection of articles written for family physicians and other family health care professionals.
- The medicines discussed in this summary are approved to treat type 2 diabetes.

### What did this chapter look at?

- Type 2 diabetes is a common condition where the levels of sugar (glucose) in the blood are increased.
- People with type 2 diabetes may also develop other conditions, such as heart failure.



 $\hat{\mathbb{G}}$   $\hat{\mathbb{G}}$   $\hat{\mathbb{G}}$   $\hat{\mathbb{G}}$ 

- Heart failure is when the heart can no longer pump blood around the body as well as it should.
- This can reduce the amount of oxygen getting to organs, which may stop working properly.
- It is important to know if medicines for treating type 2 diabetes can affect people's risk of serious heart problems.
- This chapter looks at studies to see whether newer type 2 diabetes medicines for people with diabetes affected their risk of being admitted to the hospital with heart failure.
- This chapter also talks about new and ongoing studies of blood sugar-lowering medicines in people living with heart failure who may or may not have type 2 diabetes.

### What type 2 diabetes medicines have been studied in patients with heart problems?

#### Sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors)

Help the kidneys remove extra sugar from the body when you urinate.

- Canagliflozin (Invokana®)
- Dapagliflozin (Farxiga<sup>®</sup>)
- Empagliflozin (Jardiance<sup>®</sup>)
- Ertugliflozin (Steglatro<sup>®</sup>)

## Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)

Increase incretin levels, which help the body produce more insulin and lower blood sugar levels when needed.

- Dulaglutide (Trulicity<sup>®</sup>)
- Exenatide (Byetta<sup>®</sup>)
- Exentide XR (Bydureon<sup>®</sup> and Bydureon<sup>®</sup> BCise<sup>™</sup>)
- Liraglutide (Victoza<sup>®</sup>)
- Lixisenatide (Adlyxin<sup>®</sup>)
- Semaglutide (tablet: Rybelsus<sup>®</sup>; injection: Ozempic<sup>®</sup>)

### Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors)

Help the body produce more insulin and lower blood sugar levels when needed.

- Alogliptin (Nesina<sup>®</sup>)
- Linagliptin (Tradjenta<sup>®</sup>)
- Saxagliptin (Onglyza<sup>®</sup>)
- Sitagliptin (Januvia<sup>®</sup>)

### Do these medicines affect people's risk of being admitted to the hospital with heart failure?



Type 2 diabetes medicine



Does it affect the risk of being admitted to the hospital for heart failure?

#### **SGLT2** inhibitors

- Canagliflozin (Invokana<sup>®</sup>)
- Dapagliflozin (Farxiga<sup>®</sup>)
- Empagliflozin (Jardiance<sup>®</sup>)
- Ertugliflozin (Steglatro<sup>®</sup>)

#### **GLP-1 RAs**

- Dulaglutide (Trulicity<sup>®</sup>)
- Exenatide (Byetta<sup>®</sup>)
- Exentide XR (Bydureon<sup>®</sup> and Bydureon<sup>®</sup> BCise<sup>™</sup>)
- Liraglutide (Victoza<sup>®</sup>)
- Lixisenatide (Adlyxin<sup>®</sup>)
- Semaglutide (tablet: Rybelsus<sup>®</sup>; injection: Ozempic<sup>®</sup>)

#### **DPP-4** inhibitors

- Alogliptin (Nesina<sup>®</sup>)
- Saxagliptin (Onglyza<sup>®</sup>)
- Linagliptin (Tradjenta<sup>®</sup>)
- Sitagliptin (Januvia<sup>®</sup>)

**Risk may increase** 

**Risk decreases** 

Risk stays the same

Risk stays the same

#### What are the key take-home points?

- People with type 2 diabetes who have heart problems should avoid blood sugar-lowering medicines that make them more likely to get heart failure.
- SGLT2 inhibitors may lower the risk of being admitted to the hospital with heart failure.
- Health care professionals may recommend that you take an SGLT2 inhibitor to lower certain risks related to heart failure.

#### How to say {)))

- Alogliptin (a-low-GLIP-tin). It is also called **Nesina** (ness-EE-na)
- Canagliflozin (can-A-gli-FLOW-zin). It is also called **Invokana** (in-VO-CAHN-a)
- Dapagliflozin (dap-A-gli-FLOW-zin). It is also called Farxiga (far-ZEE-ga)
- Dipeptidyl peptidase-4 (die-PEP-ti-dyl PEP-tie-days-4)
- **Dulaglutide** (DOO-la-gloo-tide). It is also called **Trulicity** (TRUE-liss-ity)
- Empagliflozin (em-PAH-gli-FLOW-zin). It is also called **Jardiance** (JAR-dee-ance)
- Ertugliflozin (err-TUG-gli-FLOW-zin). It is also called **Steglatro** (ste-GLA-trow) • Lixisenatide (LICK-see-SEN-a-tide).
- Exenatide (eck-SEN-a-tide) and exenatide XR. It is also called **Byetta** (bi-ET-ta) and Bydureon (bi-door-E-ON)
- Glucagon-like (GLUE-ca-gon-like)
- Linagliptin (lin-ah-GLIP-tin). It is also called Tradjenta (tra-GENT-a)
- Liraglutide (leer-a-GLOO-tide). It is also called **Victoza** (VIC-toe-za)
- It is also called **Adlyxin** (ADD-eh-licks-en) • Saxagliptin (SAX-a-GLIP-tin). It is also called **Onglyza** (on-GLEE-za)
- Semaglutide (sem-a-GLOO-tide). The tablet is also called **Rybelsus** (rie-BELL-sus) The injection is also called **Ozempic**
- (OH-sem-pick) • Sitagliptin (sit-ah-GLIP-tin).
- It is also called Januvia (jan-OO-vee-a)

Summary prepared by Catherine Elliot of Elevate Scientific Solutions. The author is a paid employee of Envision Pharma Group. Plain language services were funded by Boehringer Ingelheim Pharmaceuticals, Inc. Drs Skolnik and Chuong, authors of the original article, reviewed and approved this summary. This supplement was sponsored by the Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance.